Detection and quantitation of Hepatitis B virus (HBV) in less than one hour
Tanzania Clinic & Cepheid GeneXpert HIV Testing
An incredible story of a study in rapid HIV testing on mothers and babies in Rural Tanzania.
The World Health Organization estimated that 38 million people worldwide were living with HIV at the end of 2019.1
Today, measurement of blood plasma HIV-1 RNA concentration (known as HIV viral load) using nucleic
acid- based molecular diagnostic assays has been established as the standard of care in assessing
HIV-positive patient prognosis and response to antiretroviral therapy. Assessment of viral load levels
is a strong predictor of the rate of disease progression and, by itself or in combination with CD4 T-cell counts, has great prognostic value.2-7
The need for a rapid HIV viral load test with flexibility to adapt to any throughput requirements and random access for urgent samples is greater than ever because each individual patient deserves better care.
Xpert HIV-1 Viral Load is a quantitative test that provides on-demand molecular testing.
Based on the GeneXpert® technology, Xpert HIV-1 Viral Load automates the test process including RNA extraction, purification, reverse transcription and cDNA real time quantitation in one fully integrated cartridge.
* Trend report available for patients’ viral load measured multiple times on the same GeneXpert.
^ Operational throughput on Infinity-80; internal analysis.
(1) WHO HIV/AIDS Key Fact updates July 2020. Accessed July 2020. https://www.who.int/news-room/fact-sheets/detail/hiv-aids
(2) Katzenstein DA, et all. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996 Oct 10;335(15):1091-8.
(3) Mellors JW, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997 Jun 15;126(12):946-54.
(4) Mellors JW, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996 May 24;272(5265):1167-70.
(5) O’Brien WA, et al Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996 Feb 15;334(7):426-31.
(6) Ruiz L, et al. Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 x 10(6)/l. Aids. 1996 Sep;10(11):F39-44.
(7) Saag MS, et al. HIV viral load markers in clinical practice. Nat Med. 1996 Jun;2(6):625-9.
Not available in all countries. New assay version Xpert HIV-1 Viral Load XC is available in the European Union and the countries accepting the CE-mark registration only (link to new product page). For other countries where product registration is on-going, Xpert HIV-1 Viral Load assay is available. Please reach out to your Local Cepheid Representative for more information regarding the availability of the new product.
Number of Tests: 10Catalog #: GXHIV-VL-CE-10
Nash M et al., Performance of the Xpert HIV-1 viral load assay: a systematic review and meta-analysis. J Clin Microbiol. 2018 Mar 26;56(4).
Mor et al. Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Loadviral load. J Clin Microbiol 53:3458 –3465
Jordan et al., Multi-site clinical evaluation of the Xpert(®) HIV-1 viral load assay. J Clin Virol. 2016 80:27-32.
The cornerstone of the GeneXpert testing process is Cepheid's patented, self-contained, single use cartridge. Sample extraction, amplification and detection are all carried out within this self-contained "laboratory in a cartridge".